Chlorpheniramine

證據等級: L5

預測適應症: 10 個

Chlorpheniramine: From Allergic Rhinitis to Allergic Urticaria

One-Sentence Summary

Chlorpheniramine (chlorphenamine) is a first-generation H1 antihistamine that has been in clinical use since the 1950s, widely employed for the symptomatic treatment of allergic rhinitis, common cold, and allergic reactions. The TxGNN model predicts it may be effective for Allergic Urticaria, with 0 registered clinical trials and 20 publications currently identified supporting this direction. It is worth noting that this prediction largely confirms established H1 antihistamine pharmacology — international guidelines (EAACI/GA²LEN/EDF/WAO) already recommend H1 receptor antagonists as first-line therapy for urticaria — making this a validation of known use rather than a wholly novel repurposing signal.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis; common cold and flu symptoms (well-established H1 antihistamine class use)
Predicted New Indication	Allergic Urticaria
TxGNN Prediction Score	99.76%
Evidence Level	L2
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, chlorpheniramine is a potent alkylamine first-generation H1 antihistamine. It acts as a competitive, reversible antagonist at peripheral histamine H1 receptors, blocking histamine-mediated vasodilation, increased vascular permeability, pruritus, smooth muscle contraction, and the characteristic wheal-and-flare skin response. Chlorpheniramine also carries clinically significant anticholinergic activity, which may further reduce glandular secretions relevant to nasal and upper respiratory symptoms.

Allergic urticaria is driven by IgE-mediated mast cell and basophil degranulation, with histamine as the principal downstream mediator responsible for wheals, flare, and pruritus. The mechanistic connection between chlorpheniramine’s H1 blockade and allergic urticaria is therefore direct and well-established: by competitively occupying H1 receptors on dermal blood vessels and sensory nerves, chlorpheniramine attenuates both the vascular response (wheal formation) and the itch signal (pruritus). The 2024 comprehensive systematic review (PMID 35652393) explicitly lists chronic urticaria among chlorpheniramine’s confirmed clinical applications, reinforcing the TxGNN prediction.

However, prescribers should be aware that chlorpheniramine’s sedating properties and shorter duration of action are considered disadvantages relative to second-generation (non-sedating) antihistamines such as cetirizine, loratadine, and fexofenadine, which are now the preferred agents in most current urticaria treatment guidelines. Chlorpheniramine retains a clinical role in situations requiring a lower-cost option, parenteral administration (where second-generation parenteral formulations are unavailable), or where anticholinergic drying effects are additionally beneficial.

Clinical Trial Evidence

Currently no clinical trials specifically registered for chlorpheniramine in allergic urticaria were identified in this evidence search.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35652393	2024	Systematic Review	Current Reviews in Clinical and Experimental Pharmacology	Comprehensive review confirming CPM’s efficacy across allergic conditions since the 1950s; explicitly covers chronic urticaria, allergic rhinitis, asthma, and depression
1683523	1991	Comparative Study	Annals of Allergy	Head-to-head comparison of first- and second-generation H1 antihistamines; chlorpheniramine established as an effective benchmark comparator for urticaria and rhinitis
2873823	1986	Clinical Study	Asian Pacific Journal of Allergy and Immunology	142 paediatric urticaria patients; antihistamines (including CPM) used as standard care; 13.4% had chronic urticaria, 88% generalised urticaria; describes clinical patterns in Asian children
7528133	1994	Drug Review	Drugs	Loratadine reappraisal; confirms chlorpheniramine as an active comparator with similar efficacy in urticaria and allergic rhinitis in controlled comparative trials
1715267	1991	Drug Review	Drugs	Acrivastine vs. chlorpheniramine: comparable efficacy in chronic urticaria; both drugs effective in double-blind trials; chlorpheniramine used as the established active control
39265704	2024	Phase I RCT	European Journal of Pharmaceutical Sciences	Bilastine parenteral vs. dexchlorpheniramine (related first-generation compound) in histamine-induced wheal-and-flare; supports H1 antagonism for urticaria endpoints; dexchlorpheniramine is the active stereoisomer of chlorpheniramine
1981354	1990	Drug Review	Drugs	Cetirizine review in allergic rhinitis, asthma, and chronic urticaria; positions chlorpheniramine as the first-generation standard against which newer H1 antagonists are benchmarked
19348661	2009	Case Series	Journal of Dermatology	H1 antihistamine-induced urticaria in a patient with multiple antihistamine hypersensitivity; important safety signal — antihistamines can paradoxically trigger urticaria in rare individuals
31852144	2019	Case Report + Pharmacovigilance Review	Medicine	Two cases of chlorpheniramine maleate-induced anaphylaxis; retrospective pharmacovigilance database review confirms this as a rare but documented adverse event
26240795	2015	Case Report	Asia Pacific Allergy	Chlorpheniramine-induced anaphylaxis confirmed by basophil activation test; highlights the rare but serious risk of immediate hypersensitivity to the drug itself — relevant to clinical monitoring

South Africa Market Information

Chlorpheniramine is not currently registered with SAHPRA and holds no active product licences in South Africa. There are no SAHPRA-approved Professional Information (PI) documents available for this product.

South African healthcare professionals should note:

Chlorpheniramine-containing products (including combination cold/allergy preparations) may be available through informal channels or as unregistered medicines.
Any clinical use would require a Section 21 (Unregistered Medicine) authorisation from SAHPRA, or formal product registration.
The South African Essential Medicines List (EML) should be consulted to identify registered first-generation antihistamine alternatives.

Safety Considerations

As no SAHPRA-approved PI exists for chlorpheniramine in South Africa, practitioners should consult internationally recognised prescribing references (WHO Model Formulary, FDA labelling, or BNF) prior to use. Report any adverse drug reactions to SAHPRA via the MedSafe/VigiFlow system.

The following safety signals are derived from published literature and are clinically relevant:

Rare but serious hypersensitivity / anaphylaxis: Despite being an antihistamine, chlorpheniramine itself has been documented to cause IgE-mediated hypersensitivity reactions, including anaphylaxis (PMIDs 31852144, 26240795) and paradoxical urticaria (PMID 19348661). These reactions are rare but should prompt immediate recognition and management.
CNS sedation and impairment: As a first-generation antihistamine with significant CNS penetration, chlorpheniramine causes drowsiness, cognitive impairment, and psychomotor slowing. Patients must be warned against driving or operating machinery.
Anticholinergic effects: Dry mouth, urinary retention, constipation, tachycardia, and blurred vision may occur. Use with caution in elderly patients and in those with benign prostatic hyperplasia, narrow-angle glaucoma, or cardiac arrhythmias.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis for chlorpheniramine in allergic urticaria is direct and well-validated — H1 receptor blockade is the pharmacological cornerstone of urticaria management, confirmed by international treatment guidelines and a 2024 systematic review. However, this prediction reflects established pharmacology rather than a novel repurposing opportunity, and chlorpheniramine’s sedation burden positions it as a second-line option relative to registered second-generation antihistamines. The absence of any SAHPRA registration is the primary practical barrier to use in South Africa.

To proceed, the following is needed:

Regulatory pathway: Determine whether to pursue full SAHPRA registration, a Section 21 (unregistered medicine) authorisation, or identify an already-registered chlorpheniramine-containing product for the urticaria indication
Formal MOA documentation: Obtain complete DrugBank / PI-level mechanism of action data and full contraindication/warning profile for evidence dossier submission
Comparative effectiveness review: Formally evaluate chlorpheniramine against already-registered second-generation antihistamines in the South African formulary (cetirizine, loratadine, fexofenadine) — including cost, availability, and side-effect profiles
Define specific clinical niche: Identify patient populations where chlorpheniramine offers a meaningful advantage, e.g., where parenteral antihistamine is required (dexchlorpheniramine/chlorpheniramine IV/IM), paediatric dosing contexts, or low-resource settings where cost is the primary driver
South Africa-specific safety monitoring plan: Establish a pharmacovigilance protocol, particularly given the rare but documented anaphylaxis risk

⚠️ Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All content should be reviewed in conjunction with SAHPRA-approved prescribing information and current South African treatment guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.